Replies to post #161720 on Biotech Values

[jbog]

Pfizer Inc. (PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

$750,000,000 aggregate principal amount of 0.900% notes due 2017

$1,000,000,000 aggregate principal amount of 1.500% notes due 2018

$500,000,000 aggregate principal amount of floating rate notes due 2018

$1,000,000,000 aggregate principal amount of 3.000% notes due 2023

$750,000,000 aggregate principal amount of 4.300% notes due 2043

Pfizer intends to use the net offering proceeds for general corporate purposes, including (i) the repayment at maturity of the €1.85 billion outstanding of its 3.625% notes due June 2013; and (ii) pre-funding the repayment of a portion of its outstanding 4.50% notes due February 2014 and 5.50% notes due February 2014. Pfizer may use funds that are not immediately needed for these purposes to temporarily invest in short-term marketable securities or repay a portion of its outstanding commercial paper. The closing of the offering is expected to occur on June 3, 2013, subject to satisfaction of customary closing conditions.